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Schizophrenia is a highly polygenic brain disorder. 
The  main hypothesis for disease etiology in schizophre-
nia primarily focuses on the role of dysfunctional synap-
tic transmission. Previous studies have therefore directed 
their investigations toward the role of neuronal dysfunc-
tion. However, recent studies have shown that apart from 
neurons, glial cells also play a major role in synaptic trans-
mission. Therefore, we investigated the potential causal 
involvement of the 3 principle glial cell lineages in risk to 
schizophrenia. We performed a functional gene set analy-
sis to test for the combined effects of genetic variants in 
glial type–specific genes for association with schizophre-
nia. We used genome-wide association data from the larg-
est schizophrenia sample to date, including 13 689 cases 
and 18 226 healthy controls. Our results show that astro-
cyte and oligodendrocyte gene sets, but not microglia 
gene sets, are associated with an increased risk for schizo-
phrenia. The astrocyte and oligodendrocyte findings are 
related to astrocyte signaling at the synapse, myelin mem-
brane integrity, glial development, and epigenetic control. 
Together, these results show that genetic alterations under-
lying specific glial cell type functions increase susceptibil-
ity to schizophrenia and provide evidence that the neuronal 
hypothesis of schizophrenia should be extended to include 
the role of glia.
Key words: GWAS/PGC/gene set analysis/psychiatric 
disease/glia/genome-wide association
Introduction
Schizophrenia is a debilitating brain disease affecting up 
to 1% of the population.1 It is characterized by delusions, 
hallucinations, disordered speech, and deficits in emo-
tional and social behavior.2 It is highly familial with heri-
tability estimated at 81%3 and thought to be influenced 
by thousands of common alleles of small effects.4–6 Most 
efforts in understanding the cellular basis of schizophrenia 
have focused on the role of neurons. This has led to find-
ings of alterations in neuronal transmission and synapse 
cytoarchitecture as well as reports of putative neuronal 
susceptibility genes.7–11 Nevertheless, recent insights have 
implicated glial cells in several brain functions that are 
highly relevant to neurological disorders.12–15 Accordingly, 
for each of the 3 principal glial cell types, altered gene 
expression has been found in brains of schizophrenia 
patients.16,17 Furthermore, oligodendrocytes have been 
implicated by diffusion tensor imaging studies showing 
disruption of white matter tracts in schizophrenia,18,19 
and both astrocytes and microglia are associated to neu-
roinflammatory processes in several brain regions of 
schizophrenia patients.17,20 However, it still remains to be 
investigated whether glial perturbations in schizophrenia 
represent primary glial-genetic deficits and not merely sec-
ondary responses to disturbances in neuronal functioning.
Genetic association studies based on single nucleotide 
polymorphisms (SNPs) can be used to gain more insight 
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into primary genetic processes that are potentially disease 
causing. Typically, genome-wide association studies 
(GWAS) have been used for this but require large samples 
in order to identify the typically small genetic effects 
underlying complex diseases as schizophrenia.5,21–24 
Moreover, single SNP associations will not necessarily 
lead to insights in underlying molecular or cellular 
mechanisms.25,26 Alternatively, pathway analysis or 
functional gene set analysis involves testing for the 
combined effect of multiple SNPs in functionally related 
genes that individually have small effect sizes that do not 
reach significance. This approach thus takes into account 
genetic contributions that may only be observed if  the 
appropriate combination of genes is tested.25–29
Here, we used gene set analysis to obtain genetic evi-
dence for primary roles of specific glial cell type functions 
and pathways in schizophrenia. Lists of nonoverlapping 
genes for astrocytes, oligodendrocytes, and microglia, 
obtained by means of a detailed literature study, were 
subdivided into glial functional gene sets based on Gene 
Ontology (GO) annotations and expert glial knowledge. 
Using the largest schizophrenia GWAS sample to date, 
including 13 689 schizophrenia cases and 18 226 controls, 
we found a significant association with schizophrenia for 
highly specific gene sets of astrocytes and oligodendrocytes, 
and no association with any of the microglia gene sets.
Subjects and Methods
Generation of Glial Cell Type–Specific Gene Lists and 
Functional Gene Sets
A flowchart of the steps taken for generating the glial 
gene lists and subsequent functional gene sets is shown in 
figure 1. More detailed information is provided in supple-
mentary methods. Briefly, we conducted an in-depth liter-
ature study to select glial genes based on microarray gene 
expression patterns,30–38 and gene symbols and names 
were converted into human Entrez Gene IDs to assemble 
astrocyte, oligodendrocyte, and microglia gene lists.
Next, to strengthen the association of genes in these 
lists with specific astrocyte, oligodendrocyte, or microglia 
functioning, genes were removed if  found in more than 
one of these cell types or if  present in a curated exclusion 
list of general neuronal genes (supplementary figure 1; 
see supplementary methods for more information and 
exceptions). An enrichment analysis using GO biological 
processes was performed on the final, filtered astrocyte, 
oligodendrocyte, microglia, and neuronal lists to see if  
processes associated with specific cell type functions were 
uniquely enriched within each list. For each step, gene 
lists and gene IDs can be obtained from the correspond-
ing authors.
For each glial cell type (oligodendrocytes, astrocytes, 
and microglia), functional gene sets were created based 
on GO biological process annotations. Importantly, gene 
sets were built according to the hierarchical structure of 
GO (ie, higher level parental nodes were subdivided into 
more specific child nodes), resulting in an organization 
of related gene sets over a maximum of 3 levels and sub-
stantial overlap of genes between gene sets (table 1; for 
detailed information, criteria, and used software39–43 see 
supplementary methods).
Subjects
We used individual GWAS data from the Psychiatric 
Genomics Consortium (PGC1) schizophrenia working 
group5 combined with an independent GWAS sample 
from Sweden.6 Details on sample collection for PGC1 
and Swedish data sets have been described previously5,6 
and can be found in supplementary methods.
In total, 19 samples were available from 16 different 
sites. The combined sample totaled 13  833 cases and 
18 310 controls and between 250 000 and 700 000 geno-
typed SNPs per data set (supplementary table 1).
Quality Control
Site-specific quality control (QC) has been explained previ-
ously in detail.5,6 Overall, technical QC was performed on 
genotypes generated by various GWAS platforms, which 
was conducted separately at each collection site using a 
common approach. Both the PGC1 and Swedish samples 
were quality controlled following the PGC1 QC pipeline. 
Common QC parameters were applied: (a) missing rate per 
SNP <0.05 (before sample removal below), (b) missing rate 
per individual <0.02, (c) missing rate per SNP <0.02 (after 
sample removal above), (d) missing rate per SNP difference 
in cases and controls <.02, (e) SNP frequency difference 
to HapMap <0.15, and (f) Hardy-Weinberg equilibrium 
(controls) P < 10−6. The number of SNPs per study after 
QC varied between 250  000 and 680  000. Samples were 
genotyped on 4 different platforms. After basic QC, 77 986 
autosomal SNPs directly genotyped on all included GWAS 
platforms were extracted and pruned to remove SNPs in 
linkage disequilibrium (r2 > .05) or with minor allele fre-
quency <.05, leaving 39 239 SNPs suitable for robust relat-
edness testing and population structure analysis. All SNPs 
that survived quality control were mapped to genes on the 
basis of National Center for Biotechnology Information 
human assembly build 37.3 and dbSNP release 13525 (see 
supplementary methods for additional information).
Relatedness testing was done with PLINK44 (http://
pngu.mgh.harvard.edu/purcell/plink/). Pairs with genome 
identity (π ) > 0.9 were reported as “identical samples” and 
with π  > .2 as being closely related. After random shuf-
fling, one individual from each pair was excluded from 
downstream analysis. From groups with multiple related 
pairs (eg, a family), only 1 individual was kept. To con-
trol for spurious association by population stratification, 
principal component analysis was performed for each 
sample separately, and the first 10 principal components 
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were included as covariates in subsequent gene set analy-
sis. An additional 144 cases and 84 controls were removed 
as population outliers, bringing the total sample size for 
the analysis to 31 915 (13 689 cases and 18 226 controls; 
supplementary table 1).
Gene Set Analysis
Gene set analysis was done using Joint Association 
of Genetic Variants (http://ctglab.nl/software).25 Self-
contained tests were performed for each gene set using 
the sum over −log10 of SNP P values in that gene set 
as test statistic. Empirical P values (PSC) were obtained 
by permutation of the phenotype. These were com-
puted separately for each data set and then combined 
using Stouffer’s Z-score method. Bonferroni corrections 
were used to account for multiple testing (at α  =  .05) 
within each of the 3 glial groups. For gene sets that were 
significant on the self-contained test, an additional com-
petitive test was performed. For each of these gene sets, 
750 random gene sets containing the same number of 
genes were generated and tested using the self-contained 
test. The competitive P value (PCOMP) was then computed 
as the proportion of those 750 random gene sets with 
a self-contained P value lower than that of the original 
gene set. If  none of the random gene sets achieved a self- 
contained P value lower than that of the original gene 
set, the competitive P value was set to .5/750 = .00067.
Sensitivity Analysis
For the gene sets that were statistically significant based 
on PSC and PCOMP, we examined the individual contri-
bution of  each gene in that gene set. This was computed 
Fig. 1. Schematic overview showing steps (A–D) in the development of glial functional gene set lists. A) Combination of original gene 
lists from used literature sources resulted in 3 human glial gene lists. B) A neuronal list was used for filtering. The numbers of genes 
presented in the figure for each glial list represent the genes that were left after filtering for neuronal genes. C) Genes that overlapped 
between the glial cell types were also removed. The numbers of genes presented in the figure for each glial list represent the genes that 
were left after both filtering steps. D) The functional gene sets derived from the glial gene lists based on Gene Ontology (GO) are given in 




Table 1. Overview of Glial Functional Gene Sets
Astrocyte Gene Sets Oligodendrocyte Gene Sets Microglia Gene Sets
Level Functional gene sets
Number  








2 DNA metabolism 176 2 DNA metabolism 196 2 DNA metabolism 44
3  RNA metabolism 60 3  RNA metabolism 86
4   RNA processing 36 4   RNA processing 65
3   Gene transcription (P = .0088) 110 3   Gene transcription (P = .0033) 120 3   Gene 
transcription
25
2 Protein metabolism 208 2 Protein metabolism 231 2 Protein metabolism 73
3  Protein modification 137 3  Protein modification 168 3   Protein 
modification
40
3  Protein tetramerization 14
2 Lipid metabolism 146 2 Lipid metabolism (P = .0014) 85 2
2 Carbohydrate metabolism 91 2 Carbohydrate metabolism 22 3
3  Glycogen metabolism 14
2 Amino acid metabolism 69 2 Amino acid metabolism 23 2
2 Oxidation reduction 143 2 Oxidation reduction (P = .0289) 51 2
Cell communication sets
2 Cell-cell signaling 44 2 Cell-cell signaling 29
2 Signal transduction (P = 4.5E-7) 350 2 Signal transduction 265 2 Signal transduction 91
3   GPCR signaling (P = .0431) 60 3  GPCR signaling 27 3   (NF)-kappa B 
kinase 
17
3   Tyrosine kinase signaling 
(P = .0314)
27 3  Tyrosine kinase signaling 24 3
3   Small GTPase signaling 
(P = .0128)
61 3   Small GTPase signaling 66 3
3  MAPKKK cascade 20 3
3  WNT receptor signaling 20 3
Cell process sets
2 Cell cycle and division 91 2 Cell cycle and division 105 2 Transport and 
trafficking
45
2 Transport and trafficking 278 2 Transport and trafficking 257 2 Cell adhesion 20
3  Ion transport 77 3  Ion transport 45 2 Cell taxis 19
3  Protein transport 55 3  Protein transport 106
3  Vesicle-mediated transport 40 3  Vesicle-mediated transport 55
2 Cytoskeleton 47 2 Cytoskeleton 81
2 Cell adhesion (P = .0344) 79 2 Cell adhesion 67
2 Cell-specific processes 23
3  Myelination 17
3  Node processing 8
Cell development and health sets
2 Immune system 87 2 Immune system 54 2 Immune system 112
3   Response to oxidative stress 18 3   Antigen 
processing
12
3   Humoral immune 
response
12
3   Adaptive immune 
response
15
3   Innate immune 
response
11
3   Inflammatory 
response
38
3  Cytokines 18
2 Cell death and apoptosis 80 2 Cell death and apoptosis 69 2 Cell death and 
apoptosis
53
2 Cell proliferation 103 2 Cell proliferation 42 2 Cell proliferation 50
2 Miscellaneous 547 2 Miscellaneous 470 2 Miscellaneous 46
Note: GPCR, G protein–coupled receptor; MAPKKK, Mitogen-activated protein kinase kinase kinase; PSC, empirical P values; GO, Gene Ontology; 
SNPS, single nucleotide polymorphisms.
Functional gene sets were based on GO “biological processes” classification. For each glial cell type, gene sets, level indications, and numbers of genes 
are listed. Level 1 sets are composed of the complete astrocyte, oligodendrocyte, and migroglia sets (thus all genes in the glial cell type lists). Level 3 and 
4 sets represent children nodes of level 2 and 3 sets, respectively, and were all tested. The sets in bold/italic were not tested but represent the labels for the 
overarching processes and depict the range of the analyses. The sets in mere bold are the “miscellaneous” sets, and these were also included in the analyses. 
Number of genes represent the genes for which genotyped SNPs were included in the analyses. Genes could be annotated into multiple gene sets, and not 
all genes were annotated into level 2 or  
3 sets; hence, numbers of genes of lower level sets do not exactly add up to those of higher level sets. Significantly associated gene sets are italicized, with 
Bonferroni- corrected PSC values indicated in brackets. All results can be found in supplementary table 2.
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as the change in PSC for that gene set when all SNPs in 
that gene were excluded, providing a measure of  both the 
relative and absolute impact.
Results
Glial Gene Lists Are Representative of Glial Cell Type 
Functioning
In order to increase specific associations of genes in these 
lists with specific cell types, we applied 2 filtering steps 
where overlap between the different glial cell types as well 
as with a general neuronal gene list was removed. This 
resulted in enriched and nonoverlapping gene lists for 
astrocytes (1998), oligodendrocytes (1650), and microg-
lia (289). The inclusion of multiple glial cell type–specific 
markers validated the glial gene groups, eg, GFAP, APOE, 
SLC1A2, SLC1A3 (astrocytes), MBP, PLP1, MAG, CNP 
(oligodendrocytes) and CD74, CX3CR1, and multiple 
HLAs and FC receptors (microglia). Furthermore, an 
enrichment analysis for GO biological processes was per-
formed, which showed for each glial cell type, a unique 
overrepresentation of known biological functions for 
that cell type (figure 2). Overrepresentation analysis thus 
confirmed that the final, filtered lists are indeed good rep-
resentatives of glial cell type–specific functioning.
Risk of Schizophrenia Is Influenced by Astrocyte and 
Oligodendrocyte Genes
We then conducted gene set analysis using the first level 
of astrocyte, oligodendrocyte, and microglia gene-sets 
and found highly significant associations for the total 
groups of astrocyte (PSC  =  5.17 × 10
−19) and oligoden-
drocyte (PSC = 3.43 × 10
−12) genes to the risk of schizo-
phrenia, but no significant association for the microglia 
genes (PSC =  .09). Next, we used competitive testing to 
determine whether the complete sets of astrocyte and 
oligodendrocyte genes were also more significantly asso-
ciated with schizophrenia than randomly created gene-
sets matched for the same number of genes. This was 
indeed the case for the complete list of astrocyte genes 
(PCOMP = .00067), whereas the complete set of oligoden-
drocyte genes showed a nominally suggestive stronger 
association than the matched controls (PCOMP= .073).
Risk of Schizophrenia Is Influenced by Specific 
Subgroups of Glial Functioning
To gain insight into the roles of specific glial functions, 
the genes in the glial lists were functionally annotated 
resulting in 31 astrocyte, 29 oligodendrocyte, and 19 
microglia gene sets (figure 1 and table 1). We identified 
Fig. 2. Gene ontology–overrepresentation analysis for biological processes of the glial gene lists. This analysis shows that for each 
gene list, unique overrepresentation of biological processes known to be associated with the specific roles of these cells in brain 
functioning is present, with no overlap in enriched processes between the cell types. A) The astrocyte gene list shows overrepresentation 
of many metabolic functions in accordance with important roles of these cells in brain metabolic support and homeostasis. B) The 
oligodendrocyte gene list shows overrepresentation of functions associated with myelin membrane biogenesis and oligodendrocyte 
development. C) The microglia gene list shows mainly processes associated with immune system signaling. D) In the neuronal gene list, 
processes associated with synapse functioning and neurotransmitter signaling are present, indicating this list is a valid source for filtering 
of neuronal genes from the glial lists.
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that 6 of the astrocyte gene sets (signal transduction, 
tyrosine kinase signaling, G protein–coupled receptor 
[GPCR] signaling, small GTPase-mediated signaling, cell 
adhesion, and gene transcription), and 3 of the oligoden-
drocyte gene sets (lipid metabolism, oxidation-reduction, 
and gene transcription) were significantly associated with 
schizophrenia (PSC < .05), and more significantly so than 
randomly created gene sets matched for the same number 
of genes (PCOMP; table 1; supplementary table 2; supple-
mentary figure 2). No significant associations were found 
for microglia gene sets (supplementary table 2). We con-
firmed that these results for the significantly associating 
glial gene sets were consistent across the different schizo-
phrenia samples in our data set (supplementary table 3).
Significant Associations of the Glial Gene Sets  
Are Due to the Effects of Multiple Genes
To determine whether gene set associations were driven 
by a few genes or relied on the combined effect of mul-
tiple genes, we conducted a gene-based analysis. This 
showed that the associations of the gene sets did not rely 
on the effect of only a few genes but were due to the accu-
mulated effect of multiple genes with small effect (supple-
mentary table 4). These results indicate that the specific 
combinations of genes were mandate for the observed 
glial gene set associations.
Post Hoc Analyses Indicate Cell type–bound 
Mechanisms
Our glial sets were created to ensure nonoverlap between 
the 3 different glial cell types (astrocytes, oligodendro-
cytes, microglia) and a general list of neuronal genes. This 
assured that our gene sets were cell type specific. To deter-
mine whether our results would change if  we would include 
genes that are active across multiple cell types (eg, genes 
that are active in both astrocytes and oligodendrocytes), 
we reanalyzed the statistically significant gene sets with all 
overlapping genes included. We found that the astrocyte 
gene set signal transduction, GPCR signaling, tyrosine 
kinase signaling, cell adhesion, and gene transcription, 
as well as the oligodendrocyte gene set lipid metabolism, 
still significantly associated with schizophrenia, whereas 
the astrocyte gene set small GTPase-mediated signaling 
and the oligodendrocyte gene sets gene transcription and 
oxidation-reduction were no longer significantly associ-
ated with schizophrenia (supplementary table 5).
For the 6 sets that remained significantly associated 
with overlapping genes included, gene sets were also gen-
erated using all genes from all 4 central nervous system 
(CNS) cell types, thus taken cell type–bound mechanisms 
not into account at all. The gene sets cell adhesion and 
lipid metabolism lost significance (table 2). Moreover, 
while tyrosine kinase signaling, GPCR signaling and 
gene transcription did remain significant when cell type 
boundaries were not taken into account, they lost sig-
nificance when astrocyte genes were removed (table 2). 
This indicates that the associations of these groups were 
mainly driven by the astrocytic component. One excep-
tion was formed by the signal transduction set, which also 
remained significantly associated without astrocyte genes. 
Together, these results show that the significant associa-
tions of glial gene sets with schizophrenia are strongly 
dependent on genes that are specific to one cell type, with 
the exception of the signal transduction gene set.
Discussion
Converging evidence indicates direct roles for each of 
the 3 known glial cell types in modulation of neuronal 
functioning and synaptic transmission. Astrocytes are 
actively involved in bidirectional signaling with neurons 
at the “tripartite synapse.”12,14 Myelination is shown to 
Table 2. Association With Schizophrenia for Functional Gene Sets Generated From Genes Present in all 4 CNS Cell Types







Overlap With Unfiltered 
Astrocyte Gene Set Removed
Signal transduction 7.05E−12 2.19E−10 .0356 .00149 −6.9
Gene transcriptiona .0000112 .000324 .00222 .106 −2.51
GPCR signaling .0000393 .00122 .0422 .542 −2.58
Tyrosine kinase signaling .000281 .00871 .0156 .128 −1.13
Lipid metabolism .0000159 .000461 .131
Cell adhesion .0000198 .000612 .0844
Note: CNC, central nervous system; PCOMP, competitive P value; GPCR, G protein–coupled receptor.
Results are shown for each cell type in order of strength of association. “Relative impact” indicates change in log10 PSC value when 
astrocyte genes are removed from the gene set. Functional gene sets significantly associated according to Bonferroni-corrected PSC values 
are shown cursive. For these sets, PCOMP is also shown. Those more significantly associated with schizophrenia than matched controls 
according to PCOMP are shown furthermore bold. Signal transduction remained significant after removal of astrocytic expressed genes.
aFor gene transcription, oligodendrocyte genes were not included anymore.
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be plastic by experience and electrical activity,12,13 and 
microglia might be involved in activity-induced pruning 
of newly formed synapses during development and learn-
ing.12,15 Thus, it might be hypothesized that part of the 
genetic defects in schizophrenia are mediated by glial cell 
dysfunction. Schizophrenia is known to be highly poly-
genic and likely influenced by thousands of alleles each 
of small effect. Each single allele is not sufficient to cause 
the disease, but it is the accumulation of multiple risk 
alleles in a biological system that is important for schizo-
phrenia and that influences the risk to disease. Here, we 
investigated accumulation of risk alleles in specific cell 
types and cell functions. We applied a functional gene 
set analysis to investigate whether glial genes contribute 
to the occurrence of schizophrenia, and if  so, which spe-
cific glial functions may be implicated. Using a sample 
of 13 689 cases and 18 226 controls, we showed that 6 
astrocyte gene sets and 3 oligodendrocyte gene sets were 
strongly associated with schizophrenia. The significant 
associations were mainly driven by genes that were spe-
cific to 1 cell type thus supporting different roles for these 
cell types in schizophrenia pathology.
Distinct Astrocyte Gene Sets as Risk Factor  
in Schizophrenia
The astrocyte gene transcription gene set consists mainly 
of transcription factors and genes involved in epigene-
tic control mechanisms. Nearly half  of these have pre-
viously been implicated in developmental processes, 
including PAX6, which is an important factor in glial 
differentiation,45 and influences prepulse inhibition, an 
endophenotype in animal models for schizophrenia.46 
The large contribution of epigenetic control genes in 
the astrocyte gene transcription gene set, as SETDB1 
and SMARCD2,30,32 is in line with the proposed role of 
epigenetic mechanisms in schizophrenia.47 In particular, 
modifications in histone and DNA methylation patterns 
have been described as “scars” of early experience.47
The signal transduction gene set seems particularly inter-
esting because of the bidirectional signaling between neu-
rons and astrocytes at the tripartite synapse.12,14 Notably, 
3 specific subsets of signal transduction, ie, GPCR signal-
ing, tyrosine kinase signaling, and small GTPase-mediated 
signaling were also significantly associated. Astrocytic 
GPCRs can sense neurotransmitter release during synap-
tic activity and stimulate release of gliotransmitters that 
can modulate neuronal signaling.48 The astrocyte GPCR 
signaling gene set contains GMR3 and GABBR1, which 
are metabotropic receptors for the respective neurotrans-
mitters glutamate and gamma amino butyric acid. GRM3 
has previously been linked to schizophrenia. Interestingly, 
subjects with a high-risk GRM3 haplotype also had lower 
prefrontal cortical expression of the astrocytic glutamate 
transporter EEAT2 and showed impaired cognitive per-
formances.49 GRM3 and EAAT2, as well as GABBR1, 
are predominantly found at, or close to, synapses,50 sug-
gesting an involvement of astrocytes at tripartite synapses 
in the occurrence of schizophrenia. Moreover, most of 
the other genes in this group, as EDNRB and NMB, have 
been implicated in various aspects of tripartite neuron-
astrocyte signaling as well14,17,51–53 (supplementary figure 3). 
However, it should be noted that these astrocyte genes might 
also function at other locations than the tripartite synapse, 
where they may contribute to the observed changes in schizo-
phrenia. The tyrosine kinase signaling subset of signal trans-
duction consists mainly of receptor tyrosine kinases (RTKs) 
and their ligands. Recently, converging evidence shows 
involvement of many of these receptors in aspects of tri-
partite synapse processing and modulation54,55 (supplemen-
tary figure 3). For instance, the EphB3 receptor, for which 
activation by neuronal “Ephrin” has been well investigated 
and  implicated in release of gliotransmitters and modula-
tion of synaptic strength.55 Finally, the signal transduction 
subset small GTPase-mediated signaling has generally been 
linked to trafficking of cargo, eg, receptors, from and to the 
membrane,56 modulation of exocytotic release,57,58 and mor-
phology changes of perisynaptic astrocytes at the tripartite 
synapse.59 Thus, genetic alterations in the tyrosine kinase 
signaling and small GTPase-mediated signaling sets could, 
like for GPCRs, have profound influences on astrocyte mod-
ulation of synapse function in schizophrenia (figure 3b).
Cell adhesion molecules (CAM) are transmembrane 
proteins that are involved in cell-cell or cell-matrix inter-
actions. Interestingly, glial CAMs are well known players 
in promotion and/or inhibition of axon outgrowth and 
synapse formation.60,61 Interestingly, our cell adhesion 
gene set includes different cadherins (CDH4, NCad) and 
protocadherins (PCDH10, PCDH20), which enable astro-
cytes to guide synapse function and morphology,12 thus 
further indicative of an important astrocyte-neuron inter-
action element in our findings. Importantly, association 
of CAMs with schizophrenia was also found in our previ-
ous functional gene group analysis of manually curated 
synaptic gene sets,6,25 and a Kyoto Encyclopedia of Genes 
and Genomes pathway analysis in which genes were not 
restricted to specific CNS cell types.62 These findings sup-
port involvement of both neuronal and glial CAMs in 
schizophrenia and may involve altered contact of astro-
cytic perisynaptic processes with synaptic terminals.
Taken together, our astrocyte findings are thus in line 
with the novel implication of neuron-astrocyte tripartite 
communication in schizophrenia pathology (figure  3b) 
and identify astrocytes as important contributors to 
schizophrenia within the context of a neurodevelopmen-
tal disease47 (figure 3a).
Oligodendrocyte Gene Sets as Risk Factor  
in Schizophrenia
Our findings of oligodendendrocyte lipid metabo-
lism, oxidation-reduction, and gene transcription sets 
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associating with schizophrenia are in line with accumu-
lating evidence implicating oligodendrocytes in the dis-
ease.16,18 Recent studies suggest that oligodendrocyte 
and myelin dysfunction leads to changes in synapse for-
mation, function, and connectivity between related but 
anatomically different brain regions, which might lead to 
cognitive dysfunction in schizophrenia.18,19 Our data sup-
port these findings and indicate that alterations in specific 
oligodendrocyte functions might be causally involved in 
schizophrenia and associated white matter pathology.
Most of the genes in the lipid metabolism gene set 
were found to be involved in metabolism of structural 
membrane lipids of the myelin sheath.63,64 In addition, 
oligodendrocyte lipids play important roles in sorting, 
trafficking, and anchoring of myelin proteins to the myelin 
sheath.65 Interestingly, decreases in brain lipid levels and 
metabolism have been reported previously in schizophre-
nia patients.66 Moreover, several antipsychotics have been 
shown to upregulate the expression of genes involved in 
cellular fatty acid and cholesterol biosynthesis controlled 
by SREBP transcription factors.66,67 At least in the periph-
eral nervous system, SREBPs are regulators of myelin 
membrane synthesis,63 and were linked to schizophrenia.67 
Oligodendrocyte lipid metabolism dysfunction may thus 
play a role in myelin integrity and the control of intra-
cellular transport and deposition of myelin proteins and 
lipids in schizophrenia (figure 3c), an insight, which is an 
incentive to design and improve lipid-based interventions.
Most genes in the oxidation-reduction gene set are also 
involved in lipid metabolism, thereby further supporting 
the involvement of genes of the lipid metabolism group 
in schizophrenia. Genes in this group also function in 
oxidative stress, which has been implicated in develop-
ment of schizophrenia,68 albeit here specifically linked to 
oligodendrocytes for the first time (figure 3c).
The gene transcription gene set for oligodendrocytes, 
consists, like the above discussed astrocyte gene tran-
scription gene set, mainly of transcription factors and of 
molecules involved in epigenetic control. Because oligo-
dendrocyte-specific transcription factors regulate the dif-
ferentiation of oligodendrocytes and myelin membrane 
synthesis, genes encoding these transcription factors have 
been regarded as prime candidates for oligodendrocyte-
mediated dysfunction in schizophrenia. In particular, the 
DNA methylation status of sox10 correlates with oligo-
dendrocyte dysfunction in schizophrenia,69 suggesting 
that epigenetic mechanisms that affect oligodendrocyte 
development and myelinogenesis may further increase 
vulnerability to the disease (figure 3a).
Surprisingly, the “myelin” gene set, which includes the 
structural myelin proteins MAG and CNP that have been 
suggested to play a role in schizophrenia pathology,70 did 
not reach criteria for statistical association. Our findings 
thus indicate that the myelin defects reported for schizo-
phrenia might not be directly caused by genetic defects 
in structural myelin proteins themselves but are rather 
caused by genetic defects in other key oligodendrocyte 
gene sets, such as lipid metabolism or gene transcription.
No Risk Found for Microglia Gene Sets  
in Schizophrenia
Unexpectedly, we found no association of microglia 
gene sets with schizophrenia, whereas previous research 
Fig. 3. Proposed mechanism of action; how the functional glial gene sets with increased risk in schizophrenia might contribute to glial 
and neuronal function. Significantly associated functional gene sets are depicted in green, bold squares. Derived secondary processes are 
depicted in white squares. Functional gene sets that contain genes implicated at the tripartite synapse are depicted with a red border. A) 
Alterations in glial “gene transcription,” including SOX10 and PAX6 transcription factors (see main text), influence glial developmental 
processes and epigenetic mechanisms. In addition to inherent defects in central nervous system (CNS) development, these mechanisms may 
also influence vulnerability of glial cells to early environmental risk factors. B) Genetic alterations in astrocytic “receptor tyrosine kinase 
(RTK),” “G protein–coupled receptor (GPCR),” and “small GTPase-mediated signaling” processes at tripartite synapses might interfere 
with intracellular glial response to neuronal signals, causing aberrant astrocytic modulation of synapse strength via downstream processes 
as calcium signaling, gliotransmission, and neurotransmitter uptake (not in figure). Indeed, these gene sets included molecules well known 
to localize and function at the synapse, including GMR3 and GABBR1 (respectively glutamate and gamma amino butyric acid receptors) 
and the EphB3 RTK. Alterations in cell adhesion molecules, including the cadherins CDH4 and NCad, or protocadherins PCDH10 and 
PCDH20, might interfere with structural association of synapses and glia-induced plasticity. C) Genetic alterations in oligodendrocyte 
lipid metabolism may have downstream effects on myelin sheath composition and integrity. Changes in oxidation-reduction interfere with 
lipid metabolic processes and/or lead to generation of free radicals as reactive oxygen species (ROS) and subsequent myelin sheath damage 
via lipid peroxidation. See main text for further explanation.
933
Glia Gene Sets and Schizophrenia
showed microglia activation in the CNS of schizophre-
nia patients.17,20 Thus, gene sets that are most specifically 
regulated during the activation of microglia do not seem 
to genetically contribute to schizophrenia, indicating that 
previously reported microglial changes and neuroinflam-
matory symptoms involving these genes might represent 
secondary effects in response to primary schizophrenia-
induced pathology. However, it should be noted that 
because the microglia gene list mainly contains genes spe-
cifically enriched in the activated cellular state, the com-
plete set of microglia genes might not have encompassed 
all microglia functions (ie, those associated with the qui-
escent phenotype), thereby not fully appreciating the role 
of microglia in schizophrenia.
Concluding Remarks
Previous studies on schizophrenia have primarily focused 
on neuronal dysfunction. To our knowledge, this is the 
first genomic study to implicate functional gene sets 
that are highly associated with specific glial cell types. 
We found significant, replicated associations of  cell 
type–specific astrocyte and oligodendrocyte gene sets 
with schizophrenia, though not for microglia gene sets. 
Our results indicate that glial cells are key candidates 
contributing to the primary development of  underly-
ing pathological processes of  schizophrenia, which may 
have important implications for its understanding and 
treatment.
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